Abstract 981P
Background
Both tyrosine kinase inhibitors (TKIs, i.g., lenvatinib and donafenib) and anti-VEGF antibody (bevacizumab) are widely used anti-angiogenesis regimens but have different pharmacokinetics and toxicity. We aimed to compare the efficacy and safety between TKIs-based triple therapy (TkiTT) and bevacizumab-based triple therapy (BevTT) during the perioperative period in patients who underwent curative surgical resection after successful conversion for initially unresectable hepatocellular carcinoma (HCC).
Methods
272 consecutive patients who were initially diagnosed as unresectable HCC and received Lenvatinib/donafenib or bevacizumab combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) between January 2022 and December 2023 from three tertiary-care hospitals were screened, and those underwent radical surgical resection after successful tumor downstaging were finally included. Clinical, imaging and pathological parameters during the perioperative period were compared between TkiTT group and BevTT group.
Results
A total of 106 HCC patients successfully received radical resection after conversion. The conversion rate was 41.8% (46/110) and 37% (60/162) in TkiTT group and BevTT group, respectively (p =0.427). The patient characteristics, tumor features and conversion time did not differ significantly between the two groups (Table). BevTT group had a significantly longer drug withdrawal time than TkiTT group. The operation time, intra-operative bleeding, and post-operative liver function recovery did not differ significantly between the two groups. No major complication occurred in the two groups. The pathology showed significantly higher complete response rate in TkiTT group than that in BevTT group. Table: 981P
TkiTT | BevTT | P | |
Age (yr) | 59.2±9.5 | 56.5±11.7 | 0.154 |
Male (n) | 39 | 49 | 0.672 |
HBsAg positive | 39 | 52 | 1.000 |
AFP (ng/mL) | 77 | 18 | 0.377 |
PIVKA-II | 3348 | 1237 | 0.134 |
BCLC staging | 0.088 | ||
A | 20 | 30 | |
B | 15 | 9 | |
C | 11 | 21 | |
From conversion to resection (d) | 95 | 76 | 0.446 |
From TKIs/Bev withdrawal to resection (d) | 7 | 35 | ConclusionsBoth TkiTT and BevTT are effective and safe in HCC conversion therapy. TkiTT is associated with superior tumor response. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1407P - Pan-immune-inflammation value predicts the survival of patients with esophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: A pooled-analysis of two phase II trialsPresenter: Xingyuan Cheng Session: Poster session 17 1408P - DVDMS (Sinoporphyrin sodium)-mediated photodynamic therapy (PDT) vs treatment of physician’s choice in patients with advanced esophageal cancer (EC): Preliminary results of DYNA-Esophagus03, a randomized, open-labeled, multicenter phase IIIb studyPresenter: Jun Zhou Session: Poster session 17 1409P - Advancing esophageal cancer radiotherapy: AS-NeSt's 3D predictive proficiency for personalized dose distributionPresenter: Yanhua Duan Session: Poster session 17 Resources: Abstract 1410P - Efficacy of fruquintinib plus paclitaxel (F+PTX) in patients (pts) with prior immunotherapy (prior-IO): Subgroup analysis from FRUTIGA studyPresenter: Lin Shen Session: Poster session 17 1411P - AI-powered immune phenotype predicts favorable outcomes of nivolumab (niv) plus chemotherapy (chemo) in advanced fgastric cancer (AGC): A multi-center real-world data analysisPresenter: Hyung-don Kim Session: Poster session 17 1412P - Intestinal microbiota as a biological marker for pre-neoplastic lesion in gastric cancer in Amazonas, BrazilPresenter: ÁBNER PAZ Session: Poster session 17 Resources: Abstract 1413P - Multi-modal deep-learning model for real-time prediction of recurrence in early-stage esophageal cancer: A multi-modal approachPresenter: Hyun Ae Jung Session: Poster session 17 1414P - Iparomlimab and tuvonralimab (QL1706) with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: An open-label phase II studyPresenter: Wencheng Zhang Session: Poster session 17 1415P - Real-world data on the use of nivolumab plus chemotherapy for patients with metastatic GC/GEJC/EAC: A Canadian perspectivePresenter: Mustapha Tehfe Session: Poster session 17 1416P - First-line tislelizumab combined with bevacizumab and CAPOX for metastatic gastroesophageal adenocarcinoma (mGEA) with PD-L1 CPS<5: Updated results of a phase II, prospective, single-arm studyPresenter: guanghai dai Session: Poster session 17 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|